Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tiny artery block stop brain bleeds from coming back?

NCT ID NCT07751887

Disease control Sponsor: University Hospital Hradec Kralove Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial is testing whether a minimally invasive procedure called middle meningeal artery embolization (MMAE), when combined with standard surgery, can prevent chronic subdural hematoma from recurring. Chronic subdural hematoma is a collection of blood on the brain's surface that can cause pressure and symptoms. The study will include 200 adults with this condition, and they will receive MMAE either before or after surgical drainage. The main goal is to see if this combination reduces the need for repeat surgery within 90 days, while also monitoring for complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Middle meningeal artery embolization (a minimally invasive procedure that blocks blood flow to the membrane around the hematoma)
What this could lead to
If effective, this combined approach could reduce the need for repeat surgeries and improve recovery for people with chronic subdural hematoma.
What could go wrong
The procedure carries risks like stroke or bleeding, and it's unclear if it will significantly lower recurrence rates compared to surgery alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Diagnosis of a symptomatic or asymptomatic chronic or subacute subdural hematoma (cSDH) confirmed by neuroimaging (CT or MRI). * Hematoma thickness of 5 mm or greater at its widest point on baseline neuroimaging. * Patient is managed either conservatively or via standard surgical evacuation (e.g., burr-hole craniostomy) where MMAE is planned as a standalone or adjunctive treatment. * Written informed consent provided by the patient or a legally authorized representative. Exclusion Criteria: * Acute subdural hematoma requiring emergency surgical decompression due to severe neurological deficit with signs of impending herniation. * Evidence of an active intracranial infection or sepsis. * Known vascular malformation, aneurysm, or dural arteriovenous fistula as the source of the hematoma. * Severe uncorrectable coagulopathy or bleeding disorder (e.g., platelet count \<50,000/µL or INR \>2.0 that cannot be safely corrected before the procedure). * Severe renal impairment (e.g., eGFR \<30 mL/min/1.73m²) or known severe allergy to iodinated contrast media (unless adequate premedication is possible). * Life expectancy of less than 3 months due to severe comorbid conditions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic subdural hematoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic subdural hematoma

Contacts and locations

Locations

  • University Hospital Hradec Kralove

    Hradec Králové, 500 05, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.